MullerEBardayZMendelsonMKahnD.HIV-positive-to-HIV-positive kidney transplantation—results at 3 to 5 years. N Engl J Med. 2015;372:613-620. doi:10.1056/NEJMoa1408896.
2.
PrimeggiaJTimponeJGJrKumarPN.Pharmacological issues of antiretroviral agents and immunosuppressive regimens in HIV-infected solid organ transplant recipients. Infect Dis Clin North Am. 2013;27:473-486. doi:10.1016/j.idc.2013.02.011.
3.
AzarMMMalinisMFMossJFormicaRNVillaneuvaMS.Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation.Int J STD AIDS. 2017;28:447-458. doi:10.1177/0956462416651528.
4.
SawinskiDSheltonBAMehtaSet al. Impact of protease-inhibitor-based anti-retroviral therapy on outcomes for HIV+ kidney transplant recipients. Am J Transplant. 2017;17:3114-3122. doi:10.1111/ajt.14419.
5.
StockPGBarinBMurphyBet al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363:2004-2014. doi:10.1056/NEJMoa1001197.
6.
BickelMAnadolEVogelMet al. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother. 2010;65:999-1004. doi:10.1093/jac/dkq054.
7.
LeeDHMalatGEBiasTEHarhayMNRangannaKDoyleAM.Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient. Transpl Infect Dis. 2016;18:625-627. doi:10.1111/tid.12545.
8.
HanZKaneBMPettyLAJosephsonMASutorJPursellKJ.Cobicistat significantly increases tacrolimus serum concentrations in a renal transplant recipient with human immunodeficiency virus infection. Pharmacotherapy. 2016;36:e50-e53. doi:10.1002/phar.1752.
9.
TsengAHughesCAWuJSeetJPhillipsEK.Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences. Ann Pharmacother. 2017;51:1008-1022. doi:10.1177/1060028017717018.
